Scinai Immunotherapeutics

SCNI

Market cap $2.57M

JERUSALEM, March 2, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l.

JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support.

JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd.

JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during HealthIL Week 2026.

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today reported its financial results and corporate highlights for the nine months ended September 30, 2025.

Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad JERUSALEM , Oct. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai Bioservices, today announced that it has been awarded a non-dilutive grant of approximately NIS 809,000 (about $246,000) from the Israel Innovation Authority (IIA).

JERUSALEM , Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models JERUSALEM , July 29, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) biological products and providing boutique CDMO services, announced the publication of a new peer-reviewed article in the Journal of Dermatological Treatment validating the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody.

CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM , June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman's participation in the BIO International Convention 2025 (June 16–19, Boston).

The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM , June 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.